Literature DB >> 15139928

Protective immunity of SpaA-antigen producing Lactococcus lactis against Erysipelothrix rhusiopathiae infection.

H I Cheun1, K Kawamoto, M Hiramatsu, H Tamaoki, T Shirahata, S Igimi, S-I Makino.   

Abstract

AIMS: To develop an economical, safe and simple vaccination system against swine erysipelas using SpaA-antigen producing Lactococcus lactis. METHODS AND
RESULTS: The spaA gene of Erysipelothrix rhusiopathiae was inserted into a shuttle plasmid pSECE1 to construct pSECE1.3. The SpaA produced in L. lactis maintained a stable antigenicity without degrading in growth. After mice were inoculated intranasally and orally with pSECE1.3-carrying L. lactis cells, IgG and IgA specific to SpaA were detected, and all the mice survived a challenge with 100 LD(50) of E. rhusiopathiae Tama-96 in the inner thigh.
CONCLUSIONS: SpaA-producing L. lactis appears useful as an effective subunit vaccine against swine erysipelas. SIGNIFICANCE AND IMPACT OF THE STUDY: In this vaccination system, purification of the antigen and injection are unnecessary, leading to a reduced production cost, reduced labour and less stress to the animals. This vaccination system of the lactic acid bacteria should be a safe and suitable vehicle for a polyvalent vaccine.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15139928     DOI: 10.1111/j.1365-2672.2004.02283.x

Source DB:  PubMed          Journal:  J Appl Microbiol        ISSN: 1364-5072            Impact factor:   3.772


  10 in total

1.  Adjuvant effects for oral immunization provided by recombinant Lactobacillus casei secreting biologically active murine interleukin-1{beta}.

Authors:  Akinobu Kajikawa; Kazuya Masuda; Mitsunori Katoh; Shizunobu Igimi
Journal:  Clin Vaccine Immunol       Date:  2009-11-18

Review 2.  Lactococci and lactobacilli as mucosal delivery vectors for therapeutic proteins and DNA vaccines.

Authors:  Luis G Bermúdez-Humarán; Pascale Kharrat; Jean-Marc Chatel; Philippe Langella
Journal:  Microb Cell Fact       Date:  2011-08-30       Impact factor: 5.328

3.  Live bacterial vaccines--a review and identification of potential hazards.

Authors:  Ann Detmer; Jacob Glenting
Journal:  Microb Cell Fact       Date:  2006-06-23       Impact factor: 5.328

Review 4.  Mucosal delivery of therapeutic and prophylactic molecules using lactic acid bacteria.

Authors:  Jerry M Wells; Annick Mercenier
Journal:  Nat Rev Microbiol       Date:  2008-05       Impact factor: 60.633

5.  Comparison of the immune responses induced by oral immunization of mice with Lactobacillus casei-expressing porcine parvovirus VP2 and VP2 fused to Escherichia coli heat-labile enterotoxin B subunit protein.

Authors:  Diqiu Liu; Xiangqing Wang; Junwei Ge; Songmei Liu; Yijing Li
Journal:  Comp Immunol Microbiol Infect Dis       Date:  2010-03-11       Impact factor: 2.268

Review 6.  Development of vaccine delivery vehicles based on lactic acid bacteria.

Authors:  Shirin Tarahomjoo
Journal:  Mol Biotechnol       Date:  2012-06       Impact factor: 2.695

7.  Screening immune adjuvants for an inactivated vaccine against Erysipelothrix rhusiopathiae.

Authors:  Li-Jun Guan; Shi-Xuan Pei; Ji-Jian Song; Peng-Fei Zhan; Yi-Nong Han; Yun Xue; Ke Ding; Zhan-Qin Zhao
Journal:  Front Vet Sci       Date:  2022-07-26

8.  Microcrystalline Cellulose for Delivery of Recombinant Protein-Based Antigen against Erysipelas in Mice.

Authors:  Wooyoung Jeon; Yeu-Chun Kim; Minhee Hong; Sanoj Rejinold; Kyoungmoon Park; Injoong Yoon; Sungsik Yoo; Hongweon Lee; Jungoh Ahn
Journal:  Biomed Res Int       Date:  2018-06-11       Impact factor: 3.411

9.  Oral administration of Lactococcus lactis expressing Helicobacter pylori Cag7-ct383 protein induces systemic anti-Cag7 immune response in mice.

Authors:  Su-Jung Kim; Ji Young Lee; Do Youn Jun; Jae-Young Song; Woo-Kon Lee; Myung-Je Cho; Young Ho Kim
Journal:  FEMS Immunol Med Microbiol       Date:  2009-09-01

10.  Intragastric immunization with recombinant Lactobacillus casei expressing flagellar antigen confers antibody-independent protective immunity against Salmonella enterica serovar Enteritidis.

Authors:  Akinobu Kajikawa; Eiichi Satoh; Rob J Leer; Shigeki Yamamoto; Shizunobu Igimi
Journal:  Vaccine       Date:  2007-01-22       Impact factor: 3.641

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.